Rhumbline Advisers Viridian Therapeutics, Inc.\De Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Rhumbline Advisers holds 88,344 shares of VRDN stock, worth $1.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
88,344
Previous 90,826
2.73%
Holding current value
$1.9 Million
Previous $1.18 Million
70.11%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding VRDN
# of Institutions
179Shares Held
76.8MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$103 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$95.2 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$83.6 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$80.8 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$74.2 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $859M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...